Latest by Peter Rudd-Clarke

Publication

Product liability bulletin - April 2021

Published on 26 April 2021. By Gavin Reese, Partner and Mamata Dutta, Legal Director and Peter Rudd-Clarke, Legal Director and Elinor Sidwell, Associate and Sharona Zovich, Trainee Solicitor

Purple tint

Welcome to the latest edition of our product liability bulletin, looking at key news articles and cases affecting the industry. In this edition we look at: OPSS guidance following Brexit, Group Action against Vauxhall, new button battery safety campaign & much more.

Read more
Publication

Life sciences roundup

Published on 15 April 2021. By Peter Rudd-Clarke, Legal Director

Purple tint 3

Welcome to the spring quarterly roundup of regulatory developments in the life sciences sector affecting healthcare institutions - providing bite-size updates from around the industry.

Read more
Blog

Life sciences and the Brexit trade agreement of Christmas Eve 2020

Published on 26 March 2021. By Peter Rudd-Clarke, Legal Director

Purple tint

As the nation prepared for muted Christmas celebrations at the end of last year, those in industry were able to feast on the Trade and Cooperation Agreement settled between the EU and UK on 24 December 2020 (the TCA). The TCA concluded months of uncertainty for the life sciences sector. Companies had been waiting to see how far the UK government would go in agreeing to follow EU standards concerning medicines and medical devices. By the time the EU and UK finally agreed the TCA, questions over life sciences regulations had rocketed up the agenda against a backdrop of vaccines and treatments developed to combat Covid-19.

Read more
Blog

Covid-19 vaccines: an injection of politics

Published on 07 January 2021. By Peter Rudd-Clarke, Legal Director

Abstract building

A legacy of the pandemic will be greater debate, amongst politicians and the public, about how life sciences products are brought to the market.

Read more
Blog

The Nocebo Effect: study into statins signals a timely warning

Published on 17 November 2020. By Dorothy Flower, Partner and Peter Rudd-Clarke, Legal Director

Abstract building

New study into statins highlights issue of the Nocebo Effect with implications for manufacturers, insurers and society

Read more
Blog

Buyer Beware: NHSX Guidance on Artificial Intelligence

Published on 15 October 2020. By Peter Rudd-Clarke, Legal Director

Purple tint 3

NHSX Guide on AI is a useful resource for manufacturers and insurers in mitigating litigation risks

Read more
Blog

Medical Devices Regulation on the horizon

Published on 09 July 2020. By Peter Rudd-Clarke, Legal Director

Purple tint 2

The EU Regulation on Medical Devices 2017/745 (the MDR) had been due to become fully applicable on 26 May 2020.

Read more
Blog

Product Law bulletin – June 2020

Published on 05 June 2020. By Gavin Reese, Partner and Robert John, Senior Associate and Peter Rudd-Clarke, Legal Director and Elinor Sidwell, Associate

Abstract building

Welcome to the latest edition of our product law update, this month we focus on how COVID-19 is impacting product liability regulation.

Read more
Blog

The "war" against Coronavirus: implications for the Life Sciences industry when regulations are loosened

Published on 25 March 2020. By Dorothy Flower, Partner and Peter Rudd-Clarke, Legal Director

Green tint 1

Politicians have reached for military metaphors when setting out their response to the Coronavirus outbreak. Governments hope that the Life Sciences industry will win the fight against the virus by arming the healthcare sector with pharmaceutical and medical device solutions. In the first of a series of blog posts over the coming months on Coronavirus, we examine the pressures that industry must balance when responding to the call to arms.

Read more
Blog

Product Law update - Feb 2020

Published on 28 February 2020. By Gavin Reese, Partner and Peter Rudd-Clarke, Legal Director and Elinor Sidwell, Associate

Gray tint 4

Welcome to the latest edition of our product law update, this month we focus on product regulation post Brexit, the relationship between the limitation longstop and the Consumer Protection Act 1987 and product recalls of electrical goods across the UK.

Read more
Blog

General Election roundtable sheds light on key issues for the Healthcare and Life Sciences sectors.

Published on 11 December 2019. By Peter Rudd-Clarke, Legal Director

Green tint 1

Last week RPC invited guests to a roundtable to debate the UK political parties' manifesto promises affecting the healthcare and life sciences sectors. Some policies attracted criticism whilst one party bucked the national trend to emerge a winner.

Read more
Blog

A judgment that will "benefit" manufacturers facing the "risks" of products litigation

Published on 15 November 2019. By Peter Rudd-Clarke, Legal Director and Emma Kislingbury, Senior Associate

Green tint 2

In the Seroxat group litigation, the Court has endorsed using a risk/benefit approach in claims under the CPA and upheld the trial judge's ruling regarding the limited scope of the Claimants' case

Read more
Blog

The Medical Devices Regulation 2017 and good business practice

Published on 05 July 2019. By Peter Rudd-Clarke, Legal Director

Purple tint 5

When it comes to risk management, businesses in general should take note of the issues covered by the Medical Devices Regulation 2017

Read more
Blog

Vaginal mesh: the evidence

Published on 10 April 2019. By Peter Rudd-Clarke, Legal Director

Purple tint 1

NICE guidelines inform debate over the evidence for the risks and benefits of mesh products

Read more
Blog

"Move fast and break things" (just not patients)

Published on 08 February 2019. By Peter Rudd-Clarke, Legal Director

Purple tint 3

The AoMRC's report on Artificial Intelligence in Healthcare presents dilemmas for clinicians, hospital and industry

Read more
Video

Projecting into the future of the medical products sector

Published on 13 December 2018. By Emma Kislingbury, Senior Associate and Peter Rudd-Clarke, Legal Director

Gray tint 2

In the final instalment of our vlog series, we look at recently published books by Yuval Noah Harari and Stephen Hawking to help us better understand and project into the future of the medical products sector.

Read more
Video

Artificial intelligence and diagnostics in the medical sector

Published on 06 December 2018. By Emma Kislingbury, Senior Associate and Peter Rudd-Clarke, Legal Director

Purple tint 3

Our Medical and Life Sciences team take a look at the use of artificial intelligence and diagnostics in the second instalment of this 3 part vlog series.

Read more
Video

The future of the medical products sector

Published on 28 November 2018. By Peter Rudd-Clarke, Legal Director and Emma Kislingbury, Senior Associate

Purple tint 1

In the first of our vlog series we focus on the future of the medical products sector, specifically where the sector is heading and what risks and opportunities might lie ahead.

Read more
Blog

Stephen Hawking's big questions for Life Sciences

Published on 19 October 2018. By Peter Rudd-Clarke, Legal Director

Abstract building

Stephen Hawking's posthumously published "Brief Answers to the Big Questions" is a fascinating foretelling of legal challenges that the life sciences sector may face.

Read more
Blog

Fake news is bad news for patients

Published on 30 August 2018. By Peter Rudd-Clarke, Legal Director

Gray tint 4

Gee v DePuy International Limited shows that fake news in the healthcare sector is bad news for the public

Read more
Blog

US talc litigation has important lessons for UK insurers

Published on 02 August 2018. By Peter Rudd-Clarke, Legal Director

Gray tint 2

Although it is unlikely litigation involving household staples such as talcum powder could succeed in the UK, the ongoing US litigation underlines a significant trend in product liability exposures.

Read more
Blog

Court of Appeal's history lesson for claimants bringing personal injury claims

Published on 20 April 2018. By Peter Rudd-Clarke, Legal Director

Gray tint 1

Healthcare providers and manufacturers of medical products will welcome a judgment from the Court of Appeal that found against a claimant for failing to give notice of funding in time.

Read more
Blog

Using data to bring innovative products to the market … and keep them there

Published on 22 March 2018. By Peter Rudd-Clarke, Legal Director

Purple tint 3

There are now more and more opportunities to collect and use health data to innovate, improve efficiency and improve care. The same data could prove very useful in responding to the threat of litigation too

Read more
Blog

Brexit chess game to be played out at Chequers

Published on 15 February 2018. By Peter Rudd-Clarke, Legal Director

Abstract building

The Life Sciences industry demands certainty over the Government's approach to regulation after Brexit. It is hoped that Government meetings this month will achieve that.

Read more
Blog

Engagement news

Published on 29 November 2017. By Peter Rudd-Clarke, Legal Director

Green tint 2

Manufacturers and insurers may have missed Prince Harry's news on Monday in the general excitement surrounding the Government's Industrial Strategy, announced on the same day.

Read more
Blog

Welcoming new red tape

Published on 01 September 2017. By Peter Rudd-Clarke, Legal Director

Gray tint 4

The Medical Devices Regulation 2017 is good news for insurers in the life sciences sector. More data on safety and performance will be collected on products before they get to the market

Read more
Publication

Election result may be a boost for insurers of highly regulated products

Published on 13 June 2017. By Peter Rudd-Clarke, Legal Director

Purple tint

The political uncertainty following last week’s general election could in fact be good news for insurers of heavily regulated products, such as medical devices.

Read more
Publication

Election result may be a boost for insurers of highly regulated products

Published on 13 June 2017. By Peter Rudd-Clarke, Legal Director

Purple tint

The political uncertainty following last week’s general election could in fact be good news for insurers of heavily regulated products, such as medical devices.

Read more